AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up

AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up

Sept 28 (Reuters) - Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company ​and collaborate on a series ‌of studies testing their cancer treatments together. Summit's shares rose over 15% in extende...

Summit Therapeutics rises after AstraZeneca commits $2B investment (SMMT:NASDAQ)

Summit (SMMT) and AstraZeneca (AZN) ink a $2B convertible investment plus GI cancer trial collaboration for ivonescimab/ADCs—read key terms now.

Summit Therapeutics agrees to US$2B AZN investment

Summit Therapeutics agreed Sept. 28 to sell US$2B in preferred shares to AstraZeneca; conversion equates to US$18.36 per underlying common share.